Yifang Cui

Yifang Cui is a member of the Therapeutics Investment Team at the Boehringer Ingelheim Venture Fund. In this capacity, she evaluates early-stage biotechnology and life sciences startups developing novel scientific approaches to improve patient outcomes across multiple disease areas. Her investment scope encompasses tissue regeneration technologies, such as growth factor-mimetics, alongside diabetes treatments focused on beta cell regeneration and oncology platforms advancing T-cell receptor therapies for solid tumors. Cui is actively associated with several prominent portfolio companies within the fund, including AgomAb Therapeutics, DiogenX, and T-knife Therapeutics. She collaborates with fund leadership, including Frank Kalkbrenner, to deploy capital globally across the firm's corporate offices in Germany, the United States, and China. Her current focus remains strictly centered on identifying and funding novel therapeutic modalities that address significant unmet medical needs in the broader healthcare market.